Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Erythromycin lactobionate [USP:BAN:JAN]
RN: 3847-29-8
UNII: 33H58I7GLQ
InChIKey: NNRXCKZMQLFUPL-WBMZRJHASA-N

Classification Codes

  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Antibacterial
  • Drug / Therapeutic Agent
  • Gastrointestinal Agents
  • Human Data
  • Mutation Data

Molecular Formula

  • C37-H67-N-O13.C12-H22-O12

Molecular Weight

  • 1092.22
 

Names and Synonyms

Name of Substance

  • Erythromycin lactobionate
  • Erythromycin lactobionate [USP:BAN:JAN]

Synonyms

  • 4-O-beta-D-Galactopyranosyl-D-gluconic acid compd. with erythromycin
  • EINECS 223-348-7
  • Erythrocin
  • Erythrocin Lactobionate IV
  • Erythromycin lactobionate
  • Erythromycin lactobionate (1:1) (salt)
  • Erythromycin mono(4-O-beta-D-galactopyranosyl-D-gluconate) (salt)
  • Erythromycin. compd. with lactobionic acid
  • UNII-33H58I7GLQ

Systematic Names

  • D-Gluconic acid, 4-O-beta-D-galactopyranosyl-, compd. with erythromycin (1:1) (9CI)
  • Erythromycin lactobionate
  • Erythromycin mono(4-O-beta-D-galactopyranosyl-D-gluconate) (salt)
  • Erythromycin, 4-O-beta-D-galactopyranosyl-D-gluconate (salt)
  • Lactobionic acid, compd. with erythromycin (1:1)

Registry Numbers

CAS Registry Number

  • 3847-29-8

FDA UNII

  • 33H58I7GLQ

Other Registry Numbers

  • 1334-29-8
  • 1334-39-0

System Generated Number

  • 0003847298

Molecular Formulas

Molecular Formula

  • C37-H67-N-O13.C12-H22-O12

Molecular Formula Fragments

  • C12-H22-O12
  • C37-H67-N-O13
  • COMPONENT

Structure Descriptors

InChI

1S/C37H67NO13.C12H22O12/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26;13-1-3(15)10(7(18)8(19)11(21)22)24-12-9(20)6(17)5(16)4(2-14)23-12/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3;3-10,12-20H,1-2H2,(H,21,22)/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-;3-,4-,5+,6+,7-,8-,9-,10-,12+/m11/s1

InChIKey

NNRXCKZMQLFUPL-WBMZRJHASA-N

Smiles

O1[C@@H]([C@@H]([C@@H]([C@H](O)[C@@H]1O[C@H]([C@@H](CO)O)[C@@H]([C@H](C(O)=O)O)O)O)O)CO.O([C@H]1C[C@@](C)(OC)[C@@H](O)[C@@H](O1)C)[C@H]1[C@@H]([C@H]([C@@](C[C@@H](C)C(=O)[C@@H]([C@H]([C@@](O)(C)[C@@H](CC)OC([C@@H]1C)=O)O)C)(O)C)O[C@@H]1O[C@@H](C[C@@H]([C@H]1O)N(C)C)C)C

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
man TDLo intravenous 61mg/kg/1D-I (61mg/kg) SENSE ORGANS AND SPECIAL SENSES: CHANGES IN VESTIBULAR FUNCTIONS: EAR

SENSE ORGANS AND SPECIAL SENSES: TINNITUS: EAR
Archives of Internal Medicine. Vol. 143, Pg. 1263, 1983.
mouse LD50 intraperitoneal 735mg/kg (735mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 20, Pg. 1751, 1970.
women TDLo intravenous 60mg/kg/1D-I (60mg/kg) CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE

CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP
American Journal of Cardiology. Vol. 58, Pg. 666, 1986.
women TDLo intravenous 240mg/kg/4D-I (240mg/kg) SENSE ORGANS AND SPECIAL SENSES: CHANGE IN ACUITY: EAR Southern Medical Journal. Vol. 84, Pg. 1214, 1991.